Barclays
ARKG icon

Barclays’s ARK Genomic Revolution ETF ARKG Stock Holding History

Barclays’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-160,000
Closed -$4.6M – 4851
2024
Q1 		$4.6M Buy
+160,000
New +$4.81M ﹤0.01% 1918

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Barclays's ARKG Position: Q2 2026 in Review

Barclays opened a new position in ARK Genomic Revolution ETF (ARKG) in Q2 2026: 27,400 shares worth $1.15M. The stake represents ﹤0.01% of the portfolio and ranks #2708 among its holdings. This is a return to the name: Barclays previously reported a position in ARKG as recently as Q3 2025.

Barclays first reported a position in ARKG in Q4 2020 and has held it in 21 quarters since. The position peaked at $7.3M in Q3 2024. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Barclays held 27,400 shares of ARK Genomic Revolution ETF worth $1.15M as of Q2 2026.
  • ARK Genomic Revolution ETF was a new Barclays position in Q2 2026.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2708 holding.
  • Barclays first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 21 quarters since.
  • Barclays's ARK Genomic Revolution ETF position peaked at $7.3M in Q3 2024.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.